# Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies

> **NCT07016165** · PHASE4 · RECRUITING · sponsor: **Gadjah Mada University** · enrollment: 120 (estimated)

## Conditions studied

- Neutropenic Fever
- Acute Lymphoblastic Leukemia
- Acute Myeloblastic Leukemia
- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Ceftazidime
- **DRUG:** Ciprofloxacin

## Key facts

- **NCT ID:** NCT07016165
- **Lead sponsor:** Gadjah Mada University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016165, "Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07016165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*